We are a global, science-led, patient-focused pharmaceutical company. We are dedicated to transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet. | AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology and Biopharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries, and its innovative medicines are used by millions of patients worldwide. www.astrazeneca-us.com | . | AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca. | AstraZeneca in CVRM; Cardiovascular, Renal and Metabolism (CVRM), part of BioPharmaceuticals, forms one of AstraZeneca’s main disease areas and is a key growth driver for the Company. By following the science to understand more clearly the underlying links between the heart, kidneys, liver and pancreas, AstraZeneca is investing in a portfolio of medicines for organ protection by slowing or stopping disease progression, and ultimately paving the way towards regenerative therapies. The Company’s ambition is to improve and save the lives of millions of people, by better understanding the interconnections between CVRM diseases and targeting the mechanisms that drive them, so we can detect, diagnose and treat people earlier and more effectively. AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca
Asian Pacific Society of Respirology
The objectives of the APSR are the advancement and promotion of knowledge of the respiratory system in health and disease. The Society strives to encourage research, improve clinical practice through training, increase awareness of health problems and promote the exchange of knowledge among respirologists in the Asia-Pacific region and beyond.
4DMedical
4DMedical is a global leader in innovative respiratory and cardiopulmonary imaging software. Our SaaS solutions deliver non-invasive, regional, and lobar quantitative lung function analysis—giving pulmonologists and clinicians the power to act sooner and with objective data for patients with unexplained dyspnea, asthma, COPD, and other lung diseases. We also support early intervention with low-dose lung health screenings and physician-customized smoking cessation tools to help prevent disease progression. 4DMedical’s CT:VQ™ is the world’s first and only non-contrast post-processing technology that transforms routine chest CT scans into detailed, quantitative maps of lung ventilation (V) and perfusion (Q), all without injected contrast or radioisotopes. CT:VQ™ seamlessly fits into your existing workflow, delivering results directly for rapid interpretation—all from the CT you already order. You can act sooner with objective perfusion data—from the CT you already order. Enhance patient care with actionable functional data from every chest CT—accelerating your path from suspicion to confident clinical decision. | 4DMedical is a global leader in innovative respiratory and cardiopulmonary imaging software. Using advanced, non-invasive CT imaging technology, our SaaS offerings provide non-invasive, regional and lobar quantitative lung function analysis for unparalleled insights into cardiopulmonary health. With a single CT lung scan, 4DMedical provides automated, quantitative analysis that equips radiologists with detailed insights to support ordering physicians in delivering optimal patient care. Now available: CT:VQ™ is the world’s first and only non-contrast post-processing technology that transforms routine chest CT scans into quantitative, lobar ventilation (V) and perfusion (Q) maps—without contrast media, inhaled agents, or added scan time. Results are automatically delivered to PACS, ready for radiologist interpretation alongside the source CT images. For Radiologists: – One modality, one department: Complete pulmonary imaging with no new hardware or workflow steps – Add objective, functional metrics to every routine CT – Improve reporting consistency and inter-reader reproducibility – Automated, quantitative reporting and seamless PACS integration – Peer-reviewed, proven correlation with spirometry and radiologist-based metrics – Enhance your CT utility—structure and function, together in a single exam With 4DMedical, radiologists can deliver both structural and functional lung, and cardiac assessment from standard CT, enhancing diagnostic confidence, improving report value, and streamlining workflow efficiency.